CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade C4 Therapeutics, Inc. - CCCC CFD

    1.57
    1.26%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    C4 Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.59
    Open* 1.53
    1-Year Change* -82.06%
    Day's Range* 1.46 - 1.57
    52 wk Range 1.23-9.66
    Average Volume (10 days) 305.03K
    Average Volume (3 months) 10.34M
    Market Cap 72.80M
    P/E Ratio -100.00K
    Shares Outstanding 49.19M
    Revenue 16.03M
    EPS -2.85
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 1.57 0.03 1.95% 1.54 1.57 1.45
    Nov 30, 2023 1.59 0.08 5.30% 1.51 1.69 1.49
    Nov 29, 2023 1.50 -0.08 -5.06% 1.58 1.66 1.49
    Nov 28, 2023 1.55 0.05 3.33% 1.50 1.57 1.43
    Nov 27, 2023 1.48 -0.04 -2.63% 1.52 1.52 1.43
    Nov 24, 2023 1.52 0.06 4.11% 1.46 1.58 1.46
    Nov 22, 2023 1.49 0.02 1.36% 1.47 1.51 1.42
    Nov 21, 2023 1.45 -0.20 -12.12% 1.65 1.65 1.45
    Nov 20, 2023 1.66 -0.14 -7.78% 1.80 1.81 1.64
    Nov 17, 2023 1.79 0.03 1.70% 1.76 1.87 1.76
    Nov 16, 2023 1.79 0.01 0.56% 1.78 1.82 1.65
    Nov 15, 2023 1.78 0.00 0.00% 1.78 2.00 1.78
    Nov 14, 2023 1.83 0.15 8.93% 1.68 1.83 1.67
    Nov 13, 2023 1.64 0.04 2.50% 1.60 1.69 1.58
    Nov 10, 2023 1.69 -0.04 -2.31% 1.73 1.73 1.55
    Nov 9, 2023 1.73 -0.09 -4.95% 1.82 1.82 1.73
    Nov 8, 2023 1.83 0.09 5.17% 1.74 1.90 1.74
    Nov 7, 2023 1.83 0.07 3.98% 1.76 1.92 1.73
    Nov 6, 2023 1.79 0.25 16.23% 1.54 1.81 1.53
    Nov 3, 2023 1.52 0.12 8.57% 1.40 1.56 1.36

    C4 Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, February 21, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 C4 Therapeutics Inc Earnings Release
    Q4 2023 C4 Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 31.096 45.785 33.195 21.381 19.364
    Revenue 31.096 45.785 33.195 21.381 19.364
    Total Operating Expense 160.63 127.919 93.644 56.833 35.753
    Selling/General/Admin. Expenses, Total 42.789 33.254 15.204 8.728 7.126
    Research & Development 117.841 94.665 78.44 46.559 27.392
    Depreciation / Amortization 1.546 1.235
    Operating Income -129.534 -82.134 -60.449 -35.452 -16.389
    Interest Income (Expense), Net Non-Operating 1.359 -1.758 -6.512 1.832 0.685
    Other, Net 0.325 -0.007
    Net Income Before Taxes -128.175 -83.892 -66.961 -33.295 -15.711
    Net Income After Taxes -128.175 -83.892 -66.335 -34.099 -15.711
    Net Income Before Extra. Items -128.175 -83.892 -66.335 -34.099 -15.711
    Net Income -128.175 -83.892 -66.335 -34.099 -15.711
    Total Adjustments to Net Income 0 0 -8.468 -8.396
    Income Available to Common Excl. Extra. Items -128.175 -83.892 -66.335 -42.567 -24.107
    Income Available to Common Incl. Extra. Items -128.175 -83.892 -66.335 -42.567 -24.107
    Diluted Net Income -128.175 -83.892 -66.335 -42.567 -24.107
    Diluted Weighted Average Shares 48.8617 46.0417 43.0596 41.5452 41.5452
    Diluted EPS Excluding Extraordinary Items -2.62322 -1.82209 -1.54054 -1.0246 -0.58026
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -2.62322 -1.82209 -1.54054 -1.0246 -0.58026
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.664 3.759 2.854 6.754 13.834
    Revenue 2.664 3.759 2.854 6.754 13.834
    Total Operating Expense 40.232 39.987 41.147 39.242 41.218
    Selling/General/Admin. Expenses, Total 10.306 10.945 10.495 9.579 9.895
    Research & Development 29.926 29.042 30.652 29.663 31.323
    Operating Income -37.568 -36.228 -38.293 -32.488 -27.384
    Interest Income (Expense), Net Non-Operating 1.646 1.448 1.108 0.53 -0.028
    Net Income Before Taxes -35.922 -34.78 -37.185 -31.958 -27.412
    Net Income After Taxes -35.922 -34.78 -37.185 -31.958 -27.412
    Net Income Before Extra. Items -35.922 -34.78 -37.185 -31.958 -27.412
    Net Income -35.922 -34.78 -37.185 -31.958 -27.412
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -35.922 -34.78 -37.185 -31.958 -27.412
    Income Available to Common Incl. Extra. Items -35.922 -34.78 -37.185 -31.958 -27.412
    Diluted Net Income -35.922 -34.78 -37.185 -31.958 -27.412
    Diluted Weighted Average Shares 49.0636 49.0323 48.9641 48.9219 48.8237
    Diluted EPS Excluding Extraordinary Items -0.73215 -0.70933 -0.75943 -0.65324 -0.56145
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.73215 -0.70933 -0.75943 -0.65324 -0.56145
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 287.557 325.689 381.009 96.767 123.53
    Cash and Short Term Investments 276.153 309.279 371.689 90.549 36.311
    Cash & Equivalents 29.754 76.124 181.727 90.549 36.311
    Total Receivables, Net 1.473 5.716 4.484 4.623 86.438
    Accounts Receivable - Trade, Net 1.473 5.716 4.484 4.623 86.438
    Prepaid Expenses 9.931 10.694 4.836 1.595 0.781
    Total Assets 430.84 506.765 400.138 118.26 146.491
    Property/Plant/Equipment, Total - Net 77.516 35.053 16.552 18.916 20.384
    Property/Plant/Equipment, Total - Gross 85.639 41.969 22.184 22.87 22.883
    Accumulated Depreciation, Total -8.123 -6.916 -5.632 -3.954 -2.499
    Other Long Term Assets, Total 4.805 3.823 2.577 2.577 2.577
    Total Current Liabilities 44.546 51.246 43.852 33.641 23.949
    Accounts Payable 1.172 4.506 5.683 5.385 1.154
    Accrued Expenses 22.417 14.527 10.097 7.271 3.302
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 18.67 32.213 28.072 20.985 19.493
    Total Liabilities 141.606 117.159 119.347 119.228 115.246
    Total Long Term Debt 9.195 10.768 10.052 0 0
    Other Liabilities, Total 87.865 55.145 65.443 85.587 91.297
    Total Equity 289.234 389.606 280.791 -0.968 31.245
    Redeemable Preferred Stock 0 0 110.995 110.995
    Common Stock 0.005 0.005 0.004 0.001 0.001
    Additional Paid-In Capital 689.256 658.091 464.597 5.524 3.638
    Retained Earnings (Accumulated Deficit) -395.89 -267.715 -183.823 -117.488 -83.389
    Total Liabilities & Shareholders’ Equity 430.84 506.765 400.138 118.26 146.491
    Total Common Shares Outstanding 48.9662 48.6889 43.0596 41.5452 41.5452
    Short Term Investments 246.399 233.155 189.962
    Long Term Debt 9.195 10.768 10.052
    Other Equity, Total -4.137 -0.775 0.013
    Long Term Investments 60.962 142.2
    Current Port. of LT Debt/Capital Leases 2.287
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 223.686 274.387 278.452 287.557 325.456
    Cash and Short Term Investments 216.569 267.285 270.325 276.153 313.653
    Cash & Equivalents 60.971 44.881 49.476 29.754 49.551
    Short Term Investments 155.598 222.404 220.849 246.399 264.102
    Total Receivables, Net 0.5 1.028 0.528 1.473 1.488
    Accounts Receivable - Trade, Net 0.5 1.028 0.528 1.473 1.488
    Prepaid Expenses 6.617 6.074 7.599 9.931 10.315
    Total Assets 333.013 375.008 396.036 430.84 461.439
    Property/Plant/Equipment, Total - Net 72.81 74.639 76.239 77.516 79.033
    Property/Plant/Equipment, Total - Gross 80.712 82.431 84.82 85.639 86.71
    Accumulated Depreciation, Total -7.902 -7.792 -8.581 -8.123 -7.677
    Long Term Investments 29.857 19.415 34.706 60.962 52.358
    Other Long Term Assets, Total 6.66 6.567 6.639 4.805 4.592
    Total Current Liabilities 30.271 48.238 39.38 44.546 45.267
    Accounts Payable 1.276 2.247 1.034 1.172 2.37
    Accrued Expenses 18.46 20.229 19.864 22.417 21.308
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 10.535 15.427 16.195 18.67 19.339
    Total Liabilities 116.989 141.301 133.566 141.606 143.26
    Total Long Term Debt 0 0 8.621 9.195 9.052
    Long Term Debt 0 0 8.621 9.195 9.052
    Other Liabilities, Total 86.718 93.063 85.565 87.865 88.941
    Total Equity 216.024 233.707 262.47 289.234 318.179
    Common Stock 0.005 0.005 0.005 0.005 0.005
    Additional Paid-In Capital 710.552 702.068 695.605 689.256 682.288
    Retained Earnings (Accumulated Deficit) -493.629 -466.592 -430.67 -395.89 -358.705
    Other Equity, Total -0.904 -1.774 -2.47 -4.137 -5.409
    Total Liabilities & Shareholders’ Equity 333.013 375.008 396.036 430.84 461.439
    Total Common Shares Outstanding 49.2599 49.0651 49.0525 48.9662 48.9513
    Redeemable Preferred Stock 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 10.335 2.287 2.287 2.25
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -128.175 -83.892 -66.335 -34.099 -15.711
    Cash From Operating Activities -105.939 -86.965 -67.249 55.614 -16.981
    Cash From Operating Activities 1.676 1.492 1.617 1.595 1.273
    Non-Cash Items 37.339 25.525 10.646 3.136 2.948
    Changes in Working Capital -16.779 -30.09 -13.177 84.982 -5.491
    Cash From Investing Activities 58.422 -189.336 -190.505 -1.62 36.921
    Capital Expenditures -5.496 -1.277 -0.65 -1.349 -2.689
    Other Investing Cash Flow Items, Total 63.918 -188.059 -189.855 -0.271 39.61
    Cash From Financing Activities 1.147 171.4 348.932 0.244 1.961
    Issuance (Retirement) of Stock, Net 0.777 2.044 336.959 0.244 1.961
    Net Change in Cash -46.37 -104.901 91.178 54.238 21.901
    Cash Taxes Paid 0 0.143
    Cash Interest Paid 1.624 1.308 0.82
    Issuance (Retirement) of Debt, Net 0 11.973
    Financing Cash Flow Items 0.37 169.356
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -34.78 -128.175 -90.99 -59.032 -31.62
    Cash From Operating Activities -33.125 -105.939 -76.811 -48.791 -26.596
    Cash From Operating Activities 0.545 1.676 1.155 0.74 0.305
    Non-Cash Items 7.33 37.339 29.143 21.412 10.962
    Cash Interest Paid 0.43 1.624 1.203 0.828 0.473
    Changes in Working Capital -6.22 -16.779 -16.119 -11.911 -6.243
    Cash From Investing Activities 53.531 58.422 49.138 29.224 -4.004
    Capital Expenditures -0.589 -5.496 -4.006 -0.701 -0.172
    Other Investing Cash Flow Items, Total 54.12 63.918 53.144 29.925 -3.832
    Cash From Financing Activities -0.684 1.147 1.1 0.739 0.48
    Financing Cash Flow Items 0.104 0.37 0.37 0.22 0.22
    Issuance (Retirement) of Stock, Net -0.038 0.777 0.73 0.519 0.26
    Net Change in Cash 19.722 -46.37 -26.573 -18.828 -30.12
    Issuance (Retirement) of Debt, Net -0.75
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Wasatch Global Investors Inc Investment Advisor/Hedge Fund 14.6358 7199491 1483470 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 5.7251 2816205 -38834 2023-06-30 LOW
    Soleus Capital Management, L.P. Hedge Fund 5.4726 2692020 230000 2023-06-30 HIGH
    Millennium Management LLC Hedge Fund 4.819 2370504 234907 2023-07-19 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8632 1900356 -202581 2023-06-30 LOW
    Cohen (Alain J) Individual Investor 3.6699 1805252 388 2022-04-04
    Bain Capital Life Sciences Investors, LLC Investment Advisor 3.3384 1642210 0 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.6777 1317173 -1737235 2023-06-30 LOW
    TCG Crossover Management, LLC Investment Advisor 2.5951 1276574 26574 2023-06-30 MED
    Two Sigma Investments, LP Hedge Fund 2.5929 1275479 611915 2023-06-30 HIGH
    Nantahala Capital Management, LLC Hedge Fund 2.0329 1000000 1000000 2023-06-30 MED
    Dubin (Glenn R.) Individual Investor 1.6459 809637 6470 2023-10-02 LOW
    Aquilo Capital Management, LLC Investment Advisor/Hedge Fund 1.5463 760657 760657 2023-06-30 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.5358 755456 5844 2023-06-30 MED
    Citadel Advisors LLC Hedge Fund 1.361 669482 142328 2023-06-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.1554 568335 271212 2023-06-30 LOW
    AQR Capital Management, LLC Investment Advisor/Hedge Fund 1.1226 552204 -54261 2023-06-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 1.0554 519179 325018 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 1.0508 516898 190818 2023-06-30 HIGH
    Downey (Bruce L) Individual Investor 0.9952 489542 0 2023-04-06 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    C4 Therapeutics, Inc. Company profile

    About C4 Therapeutics Inc

    C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, C4 Therapeutics Inc revenues increased 38% to $45.8M. Net loss increased 26% to $83.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $2.5M to $14M (expense), Research and development - Balancing val increase of 12% to $87.1M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    490 Arsenal Way
    Suite 120
    WATERTOWN
    MASSACHUSETTS 02472
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    XRP/USD

    0.62 Price
    +0.410% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    38,849.60 Price
    -0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading